Please login to the form below

Not currently logged in
Email:
Password:

Cancer data presented at ASCO

Pharma companies, including Sanofi, Takeda and Eisa, have continued to present data from drug trials at the annual meeting for the American Society of Clinical Oncology

Pharma companies, including Sanofi, Takeda and Eisa, have continued to present data from drug trials at the 47tth annual meeting for the American Society of Clinical Oncology (ASCO).

France-based Sanofi showcased investigational drug iniparib (BSI-201), with data from a phase III trial supporting the company's decision to further develop the drug for the treatment of metastatic triple-negative breast cancer and recurrent ovarian cancer.

Despite one arm of the study not reaching statistical significance for either the overall survival endpoint or the progression free survival endpoint, lead investigator Dr Joyce O'Shaughness said she was "encouraged" by data from the trial's second and third arm.

Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).

Results showed the drug demonstrated an overall survival advantage but did not show statistically significant superiority over the control arm of patients using either supportive care or low-dose cytarabine.

Millennium, a subsidiary of Takeda specialising in Oncology, also presented data at the meeting.

Investigational small molecule inhibitor MLN4924 showed "promising anti-tumour activity in patients with advanced solid tumours" in phase I trials according to the company, while a phase II trial demonstrated the potential for the use of Adectris (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma.

Adectris is developed by Millennium in partnership with Seattle Genetics.

See ASCO's plans to make the cancer 'epidemic' a global priority.

7th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...